medigraphic.com
ISSN 1025-0298 (Electronic)
ISSN 1025-028X (Print)

2011, Number 1

Next >>

VacciMonitor 2011; 20 (1)

Meningococcal Disease. A case control study in the City of Havana, November 2003- July 2005

Pérez A, Zamora R, Pajón R

Language: Spanish
References: 26
Page: 1-7
PDF size: 202.96 Kb.


ABSTRACT

Cuba has carried out a meningococcal immunization program since 1991. Current article aims at knowing the factors associated to meningococcal disease (MD) in vaccinated persons. The universe were the nine cases under 20 years old registered as MD from November 2003 to July 2005 in the City of Havana and 34 community controls to compare to the cases and to identify associated risk factors and to evaluate existing bactericide and ELISA antibodies against the outer membrane protein from serogroup B. Only seven cases were studied because one was out of the country and the other was a dead case. The 100% of studied cases showed the meningitis form, with an average hospital stay of 9.8 days and a lethality of 14.3% (1/7). Bivariate analysis showed no maternal nursing (OR 3.17 IC 95% = 0.44-27.85) associated to the occurrence of the disease. But it was not significant (p›0.05) due to the study universe. Multivariate analysis found out association with no maternal nursing (OR 3.22 IC95%= 0.52-19.52) but it also was not significant. Mann Whitney test to compare antibody titers against B antigen in both groups, showed a very significant difference (p‹0.01) for the immune memory response to natural infection. The Cuban vaccine protects from MD caused by serogroup BC. The onset symptoms of the illness occurred with an average of four years after the second dose of the vaccine in 57 % of the cases.


REFERENCES

  1. Rosenstein NK, Perkins HA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88.

  2. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev 2006;19:142-64.

  3. Morley SL, Booy R. Epidemiology and prevention of meningococcal disease, Current Pediatrics 1997; 7:232-37.

  4. Wenger JD, Perkins BA. Patterns in emergence of epidemic meningococcal disease. In: Scheld WM, Arm strong SD, Hughes JM, eds. Emerging infections diseases. Washington, DC: ASM Press; 1998.

  5. WHO. Meningococcal vaccines polysaccharide and polysaccharide conjugate vaccines. Weekly Epidemiological Record 2002;80 (37):331-40.

  6. Roghunathan PL, Bernhardt SA, Rosenstein NE. Opportunities for control of meningococcal disease in the United States. Annul Rev Med 2004; 55:333-53.

  7. Valcárcel Novo M, Rodríguez Cruz R, Terry Molinert H. La Enfermedad Meningocócica en Cuba: Cronología de una Epidemia. La Habana: Editorial Ciencias Médicas; 1990.

  8. Pérez A, Dickinson F, Baly A, Martínes R. The Epidemiological Impact of Antimeningococcal B vaccination in Cuba. Rev Mem Inst Oswaldo Cruz 1999; 94 (4):433-40.

  9. Rico Cordeiro O, Jiménez Barrera R, Pereira Colls C. Enfermedad Meningocócica y VA-MENGOC-BC en menores de 1 año Cuba, 1983 a 1991. Rev Cubana Med Trop 1996;48(1):34-9.

  10. Pérez Rodríguez A, Dickinson Meneses F O. Vacuna VAMENGOC- BC: Su repercusión sobre la Enfermedad Meningocócica en niños de 1 a 4 años. Rev Cubana Med Trop 1999; 51 (3): 189-93.

  11. Sosa J, Maestre JL, Martínez I, Patton AS, Llanes R, Suárez O, y cols. Estudio de DNA en cepas de Neisseria meningitidis por análisis de restricción. Enf Infec y Microbiol 1998; 18(5):198- 202.

  12. Pérez AE, Dickinson F, Rodríguez M. Community acquired bacterial meningitis in Cuba: a follow up of a decade. BMC Infectious Disease 2010;10:130. Disponible en: http:// www.biomedcentral.com/1471-23344/10/130 ). Accedido: 25/ mayo/2010.

  13. Sotolongo PF. Neisseria meningitidis. Aspectos Teóricoprácticos sobre el diagnóstico, clasificación y valoración de la respuesta inmune. Serie Monográfica. Ciudad de La Habana: Ediciones Finlay;1995.

  14. Kapezynsnski DR, Williams DB, Harakeh HS, Carlone GM. Neisseria meningitidis sreogroup B Bactericidal assay. Childhood and vaccine-preventable immunology section. Atlanta, Georgia, USA: Centre for Control Disease; 1997.

  15. Ferriol X, García AM, Ochoa R, Bravo I, Blanco R, Estrada E y cols. Validación de un ELISA para la cuantificación de IgG humana anti proteína de la Neisseria meningitidis serogrupo B. Rev Cubana Med Tropical 1999; 51 (2): 99-105.

  16. Malaska SA, Gheesling L, Libutti D, Donalson K, Harakeh H, Dykes J, et al. Standardization and a Multilaboratory Comparison of Neisseria Meningitidis. Serogroup A and C Serum Bactericidal Assay. Clinical and Diagnostic Laboratory Immunology 1997; 4 (2 ):156-67.

  17. Fitzsimmons SP, Evans MK, Pearce CL, Sheridan MJ, Wientzen R, Cole MF. Immunoglobulin A subclasses in infants’ saliva and in saliva and milk from their mothers. J Pediatr 1994;124:566–73.

  18. Hanson LA. Breastfeeding provides passive and likely longlasting active immunity. Ann Allergy Asthma Immunol 1998;81:523-33.

  19. Donovan CE, Finn PW. Immune mechanisms of childhood asthma. Thorax. 1999;54:938–46.

  20. Kostinov MP, Gervazieva VB, Balabolkin II, Maksimova NM, Pereverzeva NV. The vaccinal prevention of diphtheria and tetanus in children suffering from bronchial asthma and asthmatic bronchitis. Zh Mikrobiol Epidemiol Immunobiol. 1993; 3:76–80.

  21. Wainszelbaum RN, Plager R, Larlori R. El asma en la infancia como enfermedad prolongada. Revisión farmacológica. Tratamiento por vía inhalatoria. Rev Hosp. B Aires 1994;36 (158/159):268-80.

  22. Verstraeten T, Jumaan AO, Mullooly JP, Seward JF, Izurrieta HS, DeStefano F, et al. A Retrospective Cohort Study of the Association of Varicella Vaccine Failure With Asthma, Steroid Use, Age at Vaccination, and Measles-Mumps-Rubella Vaccination. Pediatrics 2003;112:98-103.

  23. Camaraza MA, Martínez I, Ochoa R, Arnet A, Sotolongo F, Hernández D y cols. Respuesta de anticuerpos inducidos por la vacuna antimeningocócica cubana VA-MENGOC-BC frente a la cepa de Neisseria meningitidis B:4:P1.19,15 en adolescentes después de 12 años de inmunizados VacciMonitor 2006;15(3):1-4.

  24. Fernández JA, Malberty JA, Sotolongo F, Bacallao J, Camaraza MA, Nerey MC y cols. Cinética de la respuesta de anticuerpos bactericidas y de la IgG específica en individuos vacunados con VA-MENGOC-BC. Rev Cubana Hematol Immunol Hemoter 1997;13(1):38-5.

  25. Trotter CL, Andrews NJ, Kaezmarsk EB, Millar E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004,364:309-10.

  26. Holst J, Feiring B, Fuglesang JE, Harby EA, Nokleby H, Aaberge IS, Rosenqvist E. Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 2003, 21:734-7.




2020     |     www.medigraphic.com